<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="73796">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01809743</url>
  </required_header>
  <id_info>
    <org_study_id>NL42049.060.12</org_study_id>
    <nct_id>NCT01809743</nct_id>
  </id_info>
  <brief_title>Regadenoson and Adenosine</brief_title>
  <official_title>Comparison of Regadenoson (Rapiscan) and Central Intravenous Adenosine for Measurement of Fractional Flow Reserve</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lokien van Nunen</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catharina Ziekenhuis Eindhoven</source>
  <oversight_info>
    <authority>Netherlands: Medical Ethics Review Committee (METC)</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to test the accuracy of Regadenoson to induce maximal and steady
      state hyperemia as compared to central venous infusion of adenosine for assessing fractional
      flow reserve. (adenosine is considered to be the gold standard)and to investigate the time
      intervals of maximum hyperemia induced by centrally and peripherally administered
      Regadenoson.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2013</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Diagnostic</study_design>
  <primary_outcome>
    <measure>the accuracy of Regadenoson to induce maximal and steady state hyperemia</measure>
    <time_frame>participants will be followed up during hospital stay, an expected average of 1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the gold standard).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>time intervals of maximum hyperemia</measure>
    <time_frame>participants will be followed up during hospital stay, an expected average of 1 day</time_frame>
    <safety_issue>No</safety_issue>
    <description>To investigate the time intervals of maximum hyperemia induced by centrally and peripherally administered Regadenoson.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Regadenoson central - peripheral</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First bolus regadenoson administered central, second bolus administered peripheral</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regadenoson peripheral - central</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First bolus regadenoson administered peripheral, second bolus administered central</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regadenoson central - central</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First bolus regadenoson administered central, second bolus administered central</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Regadenoson peripheral - peripheral</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>First bolus regadenoson administered peripheral, second bolus administered peripheral</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regadenoson central -central</intervention_name>
    <description>To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).</description>
    <arm_group_label>Regadenoson central - central</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regadenoson peripheral - peripheral</intervention_name>
    <description>To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).</description>
    <arm_group_label>Regadenoson peripheral - peripheral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regadenoson central - peripheral</intervention_name>
    <description>To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).</description>
    <arm_group_label>Regadenoson central - peripheral</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Regadenoson peripheral - central</intervention_name>
    <description>To test the accuracy of Regadenoson to induce maximal and steady state hyperemia as compared to central venous infusion of adenosine for assessing fractional flow reserve. (adenosine is considered to be the golden standard).</description>
    <arm_group_label>Regadenoson peripheral - central</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adenosine</intervention_name>
    <description>Fractional flow reserve is measured by inducing hyperaemia using central adenosine infusion.</description>
    <arm_group_label>Regadenoson central - peripheral</arm_group_label>
    <arm_group_label>Regadenoson peripheral - central</arm_group_label>
    <arm_group_label>Regadenoson central - central</arm_group_label>
    <arm_group_label>Regadenoson peripheral - peripheral</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age 18-80 years

          -  Scheduled for invasive measurement of FFR for diagnostic and interventional purposes
             in proximal or mid segments of a coronary artery

        Exclusion Criteria:

          -  Severe aortic valve stenosis

          -  History of severe COPD

          -  Syncope or bradycardia (less than 50 beats/min)

          -  Known conduction disturbances (2nd-3rd degree heart-block, sick sinus without
             pacemaker or long QT-syndrome)

          -  Severe hypotension (RR &lt;90 mmHg)

          -  Patients in whom no access to the coronary circulation can be obtained by the femoral
             artery or in whom femoral access was problematic

          -  Coronary anatomy not suitable for FFR measurement (extremely tortuous or calcified
             coronary vessels)

          -  Previous coronary bypass surgery

          -  Recent ST elevation myocardial infarction (&lt;5 days)

          -  Recent non-ST elevation myocardial infarction (&lt;5 days) if the peak CK is &gt;1000 IU

          -  Inability to provide informed consent

          -  Pregnancy

          -  Use of methylxanthines (in the last 12 hours)

          -  Use of Dipyridamol (in the last 48 hours)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nico H.J. Pijls, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catharina Hospital Eindhoven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Lokien X van Nunen, MD</last_name>
    <role>Study Director</role>
    <affiliation>Catharina Ziekenhuis Eindhoven</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Catharina Hospital</name>
      <address>
        <city>Eindhoven</city>
        <state>Noord-Brabant</state>
        <zip>5623 EJ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>November 2013</verification_date>
  <lastchanged_date>November 11, 2013</lastchanged_date>
  <firstreceived_date>December 18, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Catharina Ziekenhuis Eindhoven</investigator_affiliation>
    <investigator_full_name>Lokien van Nunen</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Coronary artery disease</keyword>
  <keyword>Regadenoson</keyword>
  <keyword>Adenosine</keyword>
  <keyword>Maximal hyperemia</keyword>
  <keyword>Fractional flow reserve</keyword>
  <keyword>FFR</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Myocardial Ischemia</mesh_term>
    <mesh_term>Coronary Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Adenosine</mesh_term>
    <mesh_term>Regadenoson</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
